Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

n and our financial performance.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to successfully commercialize Cinryze;
  • our ability to receive regulatory approval for the use of Cinryze for the acute treatment of HAE;
  • the availability of third party payer reimbursement for Cinryze patients;
  • our ability to develop a clinical development program for maribavir;
  • approval of products which are currently marketed for other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Vancocin or Cinryze;
  • fluctuations in wholesaler order patterns and inventory levels;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for the product;
  • changes in prescribing or procedural practices of physicians, including off-label prescribing of products competitive with Vancocin and Cinryze;
  • the timing of regulatory submissions and approvals;
  • actions by the FDA, EMEA and the Internal Revenue Service or other government regulatory agencies;
  • decreases in the rate of infections for which Vancocin is prescribed or decreases in the sensitivity of the relevant bacteria to Vancocin;
  • an impairment of our intangible assets if our market capitalization remains less than our book value;
  • the timing and results of anticipated events in our clinical development programs; and
  • the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring produ
    '/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 The ... Spain , available today on PharmaBoardroom.com ... the Eurozone crisis that rocked the Spanish economy in 2009, ... Spanish pharma community has remained pragmatic in times of trouble. ... is still the fifth biggest European market, and the general ...
(Date:9/18/2014)... A novel robotic system that can operate inside ... tested as part of a biomedical research partnership program ... aim of determining if the robot, in conjunction with ... more accurate, less costly, and less discomforting for the ... deliver prostate cancer therapies with greater precision. , Developed ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global and Chinese Stem Cell Industry Report, ... Stem cells are undifferentiated biological cells that can differentiate ... produce more stem cells. Stem cell therapy can be ... of hematological system disease), nervous system diseases, damage or ...
(Date:9/18/2014)... 18, 2014  U.S. biotech company Kultevat ... license for technology developed by the Donald Danforth ... plants, including for applications in production of natural rubber ... technology was developed under the direction of Roger ... former president of the Danforth Plant Science Center, and ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Kultevat obtains license of gene switch technology 2
... , ... wastes has never been easier, or less smelly, thanks to a new indoor composting ... composting bucket collects food scraps in an airtight bucket. Bokashi, made using SCD,s probiotic ... , ...
... May 18 Caliper Life Sciences, Inc. (Nasdaq: CALP ... life sciences research, today announced that it reached an agreement to sell ... product lines to Biotage AB for $16.5 million in cash. ... "Divesting these product ...
... May 17 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" or the "Company" ... for the first quarter ended March 31, 2010 . , ... Results for the Quarter Ended March 31, 2010 , ... The Company recorded $49.06 million of revenues for ...
Cached Biology Technology:All Seasons Indoor Composter™ and All Seasons Bokashi™ Provide Easy Way to Recycle Food Waste Right in Your Kitchen 2All Seasons Indoor Composter™ and All Seasons Bokashi™ Provide Easy Way to Recycle Food Waste Right in Your Kitchen 3Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 2Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 3Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 4Dragon Pharma reports 2010 first quarter financial results 2Dragon Pharma reports 2010 first quarter financial results 3Dragon Pharma reports 2010 first quarter financial results 4Dragon Pharma reports 2010 first quarter financial results 5
(Date:9/18/2014)... creatively manipulate spoken language is unique to humans. "The ... years of human evolution to make this possible are ... we now have," says Wolfgang Enard, Professor of Anthropology ... understand the molecular biological basis of language Enard has ... his latest study, undertaken in collaboration with scientists at ...
(Date:9/18/2014)... happy-go-lucky characters, so you might expect that most would ... fact some dogs are distinctly more pessimistic than others, ... "This research is exciting because it measures positive and ... offers researchers and dog owners an insight into the ... Melissa Starling, from the Faculty of Veterinary Science. Her ...
(Date:9/18/2014)... stressed they are often grouchy, grumpy, nasty, distracted or ... EPFL have just highlighted a fundamental synaptic mechanism that ... of social skills and cognitive impairment. When triggered by ... the brain. This was revealed by a work published ... team went to look for answers in a region ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Dogs can be pessimists too 2Dogs can be pessimists too 3How stress tears us apart 2
... September 4, 2012The use of RNA in nanotechnology applications ... of new therapeutic compounds. Key technical challenges remain, though, ... of RNA molecules in nanotechnology approaches are presented in ... a peer-reviewed journal from Mary Ann Liebert, Inc. ...
... from the University of Minnesota,s College of Veterinary Medicine, ... have found that antimicrobial growth promoters administered to swine ... animal,s intestinal track, resulting in an accelerated rate of ... routinely administered to swine to treat illness and to ...
... German . Researchers today can provide nerve cells ... control them with light. The Gertrud Reemtsma Foundation is now ... who initiated and were instrumental in promoting the still young ... Institute of Biophysics in Frankfurt, Karl Deisseroth of Stanford University ...
Cached Biology News:Zülch Prize 2012 for founders of optogenetics 2Zülch Prize 2012 for founders of optogenetics 3Zülch Prize 2012 for founders of optogenetics 4
... Pocket Surveyor software provides local instrument ... Surveyor HPLC Systems. The software operates ... popular Windows Pocket PC 2002 O/S ... connect directly to their Surveyor quaternary ...
Reported to support murine B lymphocytes, hematopoietic tissue from bone marrow, B cells stimulated with lipopolysaccharide, T lymphocytes, and a variety of hybrid cells....
... Many modifications of Eagle's ... the original formulation. The most ... Modified Eagle's,Medium. DME is a ... Eagle [MEM] that contains a ...
... is a fixative useful for routine procedures. ... is stable and will decalcify small bone ... can be stained successfully with most stains, ... stabilizes red blood cell membranes and cosinophil ...
Biology Products: